CoChat

Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice

Open access
Lonial, Sagar, Rajkumar, S Vincent, Mateos, Maria Victoria · 2022 · The Lancet Haematology
Cited by 9

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Smouldering multiple myeloma is a precursor condition that has been relegated to observation for more than 40 years on the basis of the pooled risk of progression relative to the risks of treatment. In the modern era of myeloma therapy, efficacy and toxicity of initial therapy have improved, as have tools for assessing risk of progression of this disease. The combination of these two advances has resulted in an explosion in the number of trials testing new drugs in patients with smouldering multiple myeloma, with the goal of preventing patients from developing the need for intensive treatment or of eliminating the malignant clone in totality. Two phase 3 trials have now shown a significant benefit of early intervention in the highest risk group of patients, leading to the discussion and approach described in this Viewpoint. Ongoing uncertainties include the duration of therapy, acceptable risks, and intensity of treatment (curative vs preventive), all of which are being tested in ongoing trials. Finally, common methods for risk stratification are crucial for allowing comparison across trials, and the 20/2/20 (Mayo 2018) criteria might be one such method, on the basis of their simplicity and broad availability. A focus on phase 3 trials is key to moving the field forward in a way that answers these questions and ultimately improves outcomes for patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2352-3026(21)00335-5

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 9

  1. Kyle, 1980, Smoldering multiple myeloma, N Engl J Med, 302, 1347, 10.1056/NEJM198006123022405 · DOI · Paper page
  2. Mateos, 2016, Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial, Lancet Oncol, 17, 1127, 10.1016/S1470-2045(16)30124-3 · DOI · Paper page
  3. Lonial, 2020, Randomized trial of lenalidomide versus observation in smoldering multiple myeloma, J Clin Oncol, 38, 1126, 10.1200/JCO.19.01740 · DOI · Paper page
  4. Lakshman, 2018, Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria, Blood Cancer J, 8, 59, 10.1038/s41408-018-0077-4 · DOI · Paper page
  5. Puíg, 2020, Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS), Proc Am Soc Clin Oncol, 38
  6. Mateos, 2017, Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd, Blood, 130, 402
  7. Mateos, 2020, International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM), Blood Cancer J, 10, 102, 10.1038/s41408-020-00366-3 · DOI · Paper page
  8. Ravi, 2016, Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma, Blood Cancer J, 6, e454, 10.1038/bcj.2016.65 · DOI · Paper page
  9. Rajkumar, 2014, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, 15, e538, 10.1016/S1470-2045(14)70442-5 · DOI · Paper page

Cited by

See all 9

Metadata

Authors
Lonial, S., Rajkumar, S. V., & Mateos, M. V.
Venue
The Lancet Haematology
Publisher
Elsevier BV
Published
2022-02
Volume
9
Issue
2
Pages
e162-e165
ISSN
2352-3026 (ISSN-L)
OpenAlex
W4210497283
Cited by
9
References
3
FWCI
1.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice. https://app.cochat.ai/papers/10.1016/s2352-3026(21)00335-5
The paper
Lonial, S., Rajkumar, S. V., & Mateos, M. V. (2022). Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(21)00335-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.